Lead Sponsor

First Affiliated Hospital of Ningbo University

Age

70 - 100 years

Sex

ALL

Healthy Volunteers

No

•1. Age ≥ 70 years;
•2. ECOG score 0-3;
•3. Rated as "unfit" or "frail" on the simplified geriatric assessment (sGA);
•4. Histologically confirmed CD20-positive diffuse large B-cell lymphoma \[diagnostic criteria according to WHO 2016\], excluding transformed type 2 DLBCL;
•5. Previously untreated, newly diagnosed patients;
•6. Cardiac, hepatic, and renal function: creatinine \< 2 times the upper limit of normal (ULN); ALT (alanine aminotransferase) / AST (aspartate aminotransferase) \< 2.5 x ULN; total bilirubin \< 2 x ULN;
•7. At least one measurable lesion;
•8. Intolerance to standard CHOP chemotherapy regimen or unwillingness to receive chemotherapy;
•9. Sufficient understanding and voluntary signing of the informed consent form.

•1. Patients with central nervous system involvement at the onset of the disease;
•2. Known human immunodeficiency virus (HIV) infection;
•3. Pregnant or lactating women;
•4. Other tumors requiring treatment;
•5. Uncontrolled active infection;
•6. Active hepatitis with HBV-DNA copy number unable to be controlled within 2000/mL despite antiviral treatment;
•7. Individuals who cannot understand, comply with the study protocol, or sign the informed consent form.

Related studies

NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more

NCT07200375 · Diffuse Large B-Cell Lymphoma

NCT03223610 · Lymphoma, Non-Hodgkin Lymphoma, and more

NCT03418038 · Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, and more

NCT07523737 · Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)

Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy